此项结果表明,科济生物靶向GPC3的CAR-T疗法在人体内安全可控,且在晚期肝细胞癌患者中表现出一定的疗效。而基于新一代CAR-T技术平台CycloCAR开发的CT017,体内研究结果表明,在3种小鼠实体瘤模型(胰腺癌、乳腺癌和肝癌)中并且无需环磷酰胺预处理的条件下,较传统CAR-T细胞或IL-7/CCL19共表达的CAR-T细胞表现出更为显著的疗
Overall, the molecular receptor NKBB significantly increased the persistence of GPC3 CAR-T cells, and GC3328z-NKBB CAR-T cells possessed potent anti-HCC activity in mice, providing a new strategy for the potential improvement of adoptive T cell therapy in the treatment of HCC....
到目前为止，针对G K'3的磁共振成像、正电子发射断层扫描和近红外成像 已被用于肝癌的早期检测，研发了各种针对GPC3 的免疫治疗方案，包括使用人源化的抗GPC3抗体 治疗、多肽疫苗治疗、CAR-T等的治疗。用于HCX 的诊断具有一■定的价值，基于此，本实验N时检测 GPC3、AFP、C EA及CA199在HCC 患者血清中的 ...
过去十年,肝癌治疗领域已取得显著进展,晚期患者生存期实现突破性逆转。除了上文提到的这款靶向GPC3的自体CAR-T疗法——C-CAR031外,多款创新药物/新技术正处于研发阶段,为肝癌患者带来更长生存的希望! 更大的好消息是,目前,C-CAR031临床研究正在进行中,这也意味着中国患者也有机会获得这款抗癌新疗法的帮助。对此感...
12月20日,西比曼生物科技集团(以下简称“西比曼”)宣布,公司申办的“靶向GPC3装甲型嵌合抗原受体自体T细胞注射液C-CAR031(AZD7003)治疗GPC3+晚期/复发性肝细胞癌的I/II期临床研究”(STARLIGHT研究)全国研究者会已于此前11月在浙江杭州成功召开。 此前,C-CAR031细胞注射液已于2024年4月正式获批临床默示许可,并...
In a mouse xenograft model of HCC using the Hep3B cell line, the CAR-T cells induced significant tumor regressions, with the potency edits conferring even greater tumor control. Disruption of the endogenous TGF尾R2 gene causes greater attenuation of TGF尾 signaling compared to the knock-in of ...
GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.KWON, BYOUNG S.SON, HYUNTAELEE, HYE MIKIM, KWANGHEECHUNG, JIWONCHANG, YOUNG GYOONYI, BO-RIMLEE, JUNGYUNLEE, SEUNGHYUNIM, SUN-WOO
GPC3 CAR compositions provided herein can be used for the treatment of certain cancers.KWON, BYOUNG S.SON, HYUNTAELEE, HYE MIKIM, KWANGHEECHUNG, JIWONCHANG, YOUNG GYOONYI, BO-RIMLEE, JUNGYUNLEE, SEUNGHYUNIM, SUN-WOO
The HCC microenvironment is rich of the immunosuppressive cytokine TGFβ, prompting us to armor the low affinity GPC3 CAR-T cells with a dominant-negative TGFβRII (TGFβRIIDN). In vitro, expression of TGFβRIIDN nearly abolished TGFβ-induced SMAD2/3 phosphorylation and reduced suppression of...
m) competes for binding to human GPC3 with antibody 7H1; n) competes for binding to human GPC3 with antibody 4G7; o) competes for binding to human GPC3 with antibody 15G1; and/or p) competes for binding to human GPC3 with antibody 4A11. In some embodiments, the characteristics of the...